Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly’s drug.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
Brought to you by www.srnnews.com
SRN News — View the original story at SRNNews.com.